{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Intraepithelial+Neoplasia",
    "query": {
      "condition": "Oral Intraepithelial Neoplasia"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T04:24:15.710Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05463796",
      "title": "InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer Risk",
        "Cancer Predisposition Syndrome",
        "Hereditary Cancer Prediction",
        "Childhood Cancer Survivors",
        "Adult Cancer Survivors",
        "IARC Carcinogens",
        "Smoking History",
        "Lung Cancer",
        "Ductal/Lobular Carcinoma",
        "Barrett Esophagus",
        "Pancreatic Precursor Lesions",
        "Colonic Dysplasia/Adenomata",
        "Non-Alcoholic Fatty Liver Disease",
        "Non Alcoholic Steatohepatitis",
        "Cirrhosis",
        "High Grade Prostatic Epithelial Neoplasia",
        "High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ",
        "Adenomatous Hyperplasia",
        "High-risk Oral Precancerous Diseases",
        "Melanocytic Lesion, Adult",
        "Hematologic Malignancy",
        "Lung; Node",
        "Serous Tubal Intraepithelial Carcinoma",
        "Endometrial Intraepithelial Neoplasia",
        "Cervical and Endocervical Carcinoma in Situ",
        "Vulvar Intraepithelial Neoplasia",
        "Nephrogenic Rests",
        "Benign Bone Lesions With Risk of Malignant Degeneration",
        "Giant Cell Tumor",
        "Osteochondroma",
        "Spitz Nevus"
      ],
      "interventions": [
        {
          "name": "Samples",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5000,
      "start_date": "2023-04-25",
      "completion_date": "2032-03-25",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-06-11T04:24:15.710Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05463796"
    },
    {
      "nct_id": "NCT00402779",
      "title": "Erlotinib Prevention of Oral Cancer (EPOC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Oral Cancer"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 303,
      "start_date": "2006-11-03",
      "completion_date": "2018-06-04",
      "has_results": true,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-06-11T04:24:15.710Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • New York, New York + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402779"
    },
    {
      "nct_id": "NCT07149220",
      "title": "Fenretinide Mucoadhesive Patch: Evaluation of Oral Cancer Prevention Efficacy in Adults With Premalignant Oral Lesions.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Oral Leukoplakia",
        "Oral Dysplasia"
      ],
      "interventions": [
        {
          "name": "Mucoadhesive fenretinide-releasing system (FMS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 25,
      "start_date": "2025-09-01",
      "completion_date": "2026-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-06-11T04:24:15.710Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07149220"
    },
    {
      "nct_id": "NCT05266898",
      "title": "Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Papillomavirus Vaccines",
        "Human Immunodeficiency Virus",
        "Papillomavirus Infection",
        "Serology",
        "Cervical Intraepithelial Neoplasia",
        "Anal Intraepithelial Neoplasia",
        "Oral Cavity Infection"
      ],
      "interventions": [
        {
          "name": "Human papillomavirus 9-valent vaccine, recombinant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "human papillomavirus vaccine, recombinant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Louisiana State University Health Sciences Center in New Orleans",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 250,
      "start_date": "2022-11-30",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-04-18",
      "last_synced_at": "2026-06-11T04:24:15.710Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05266898"
    },
    {
      "nct_id": "NCT00003223",
      "title": "SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "fenretinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "1997-12",
      "completion_date": "2000-03",
      "has_results": false,
      "last_update_posted_date": "2012-07-24",
      "last_synced_at": "2026-06-11T04:24:15.710Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • Kansas City, Kansas • Lexington, Kentucky + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003223"
    },
    {
      "nct_id": "NCT02882282",
      "title": "Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oral Cavity Carcinoma",
        "Oral Intraepithelial Neoplasia"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-06-14",
      "completion_date": "2025-07-14",
      "has_results": true,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-06-11T04:24:15.710Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02882282"
    },
    {
      "nct_id": "NCT00212381",
      "title": "Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cervical Dysplasia"
      ],
      "interventions": [
        {
          "name": "di indolylmethane (DIM)",
          "type": "DRUG"
        },
        {
          "name": "Red rice bran",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "New York Presbyterian Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 62,
      "start_date": "2000-09",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-06-11T04:24:15.710Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00212381"
    },
    {
      "nct_id": "NCT00001073",
      "title": "Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections",
        "Cervix, Dysplasia"
      ],
      "interventions": [
        {
          "name": "Isotretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "13 Years and older · Female only"
      },
      "enrollment_count": 150,
      "start_date": null,
      "completion_date": "2001-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-06-11T04:24:15.710Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001073"
    },
    {
      "nct_id": "NCT05853783",
      "title": "Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mouth Diseases"
      ],
      "interventions": [
        {
          "name": "STRATICYTE™ Test",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Proteocyte Diagnostics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2023-01-01",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2024-11-07",
      "last_synced_at": "2026-06-11T04:24:15.710Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Loma Linda, California • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05853783"
    },
    {
      "nct_id": "NCT01192204",
      "title": "Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Mouth",
        "Intraepithelial Neoplasia"
      ],
      "interventions": [
        {
          "name": "10% FBR containing bioadhesive gel",
          "type": "DRUG"
        },
        {
          "name": "placebo gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 41,
      "start_date": "2010-10",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2015-08-14",
      "last_synced_at": "2026-06-11T04:24:15.710Z",
      "location_count": 3,
      "location_summary": "Louisville, Kentucky • Chapel Hill, North Carolina • Columbus, Ohio",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01192204"
    }
  ]
}